RT Journal Article
SR Electronic
T1 Chimeric TK-NOG Mice: A Predictive Model for Cholestatic Human Liver Toxicity
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 274
OP 280
DO 10.1124/jpet.114.220798
VO 352
IS 2
A1 Xu, Dan
A1 Wu, Manhong
A1 Nishimura, Sachiko
A1 Nishimura, Toshihiko
A1 Michie, Sara A.
A1 Zheng, Ming
A1 Yang, Zicheng
A1 Yates, Alexander John
A1 Day, Jeffrey S.
A1 Hillgren, Kathleen M.
A1 Takeda, Saori Takedai
A1 Guan, Yuan
A1 Guo, Yingying
A1 Peltz, Gary
YR 2015
UL http://jpet.aspetjournals.org/content/352/2/274.abstract
AB Due to the substantial interspecies differences in drug metabolism and disposition, drug-induced liver injury (DILI) in humans is often not predicted by studies performed in animal species. For example, a drug (bosentan) used to treat pulmonary artery hypertension caused unexpected cholestatic liver toxicity in humans, which was not predicted by preclinical toxicology studies in multiple animal species. In this study, we demonstrate that NOG mice expressing a thymidine kinase transgene (TK-NOG) with humanized livers have a humanized profile of biliary excretion of a test (cefmetazole) drug, which was shown by an in situ perfusion study to result from interspecies differences in the rate of biliary transport and in liver retention of this drug. We also found that readily detectable cholestatic liver injury develops in TK-NOG mice with humanized livers after 1 week of treatment with bosentan (160, 32, or 6 mg/kg per day by mouth), whereas liver toxicity did not develop in control mice after 1 month of treatment. The laboratory and histologic features of bosentan-induced liver toxicity in humanized mice mirrored that of human subjects. Because DILI has become a significant public health problem, drug safety could be improved if preclinical toxicology studies were performed using humanized TK-NOG.